VERA receives FDA accelerated approval for TRUTAKNA; Q2 net loss widens 43% to $109.5M

Filed August 10, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read

Key Changes

• high

  FDA granted accelerated approval to TRUTAKNA (atacicept) on July 7, 2026, for IgAN treatment based on 42% proteinuria reduction vs. placebo in ORIGIN 3 trial. First commercial revenue expected Q3 2026, marking transition from clinical-stage to commercial operations.

  MD&A: FDA Approval verify on EDGAR →
• high

  Q2 2026 net loss widened 43% to $109.5M from $76.5M in Q2 2025; operating loss expanded 40% to $112.5M. Six-month cash burn reached $206.8M as the company scaled commercial infrastructure ahead of launch.

  MD&A: Operating Results verify on EDGAR →
• high

  FDA approval triggered $20M milestone payment. Total regulatory milestone obligations of $35M in first half of 2026.

  Notes: Ares Milestones view on EDGAR →